Earlier this month the House Energy and Commerce Committee’s subcommittee on Government Oversight and Investigations held its second hearing on the 340B Drug Discount Program. The hearing followed on the heels of a July 18th hearing in which officials from the Health Resources and Services Administration (HRSA), the Government Accountability Office (GAO), and the Department of Health and Human Services Office of Inspector General (HHS-OIG) testified about the challenges faced in overseeing the 340B Program.
This hearing was called Examining How Covered Entities Utilize the 340B Drug Pricing Program. Representatives of five different covered entities were asked to address three questions in their testimony:
- How much do 340B Covered Entities save when purchasing 340B drugs?
- How are those savings tracked?
- How are those savings used?
However, it was the follow-up questions from subcommittee and committee members that may indicate where Congress is headed in legislating changes to the 340B Program. Continue Reading Six Key Follow-Up Questions Asked by Congress in 340B Hearing